Formation of an internal FDA Nanotechnology Task Force
Key points
- Acting Commissioner of Food and Drugs Andrew C. von Eschenbach, M.D., today announced the formation of an internal FDA Nanotechnology Task Force.
- The new task force is charged with determining regulatory approaches that encourage the continued development of innovative, safe and effective FDA-regulated products that use nanotechnology materials.
- The task force will identify and recommend ways to address any knowledge or policy gaps that exist so as to better enable the agency to evaluate possible adverse health effects from FDA-regulated products that use nanotechnology materials.
- "As this exciting new area of science develops, FDA must be positioned to address both health promotion and protection challenges that it may present," said Dr. von Eschenbach.
Acting Commissioner of Food and Drugs Andrew C. von Eschenbach, M.D., today announced the formation of an internal FDA Nanotechnology Task Force.
The new task force is charged with determining regulatory approaches that encourage the continued development of innovative, safe and effective FDA-regulated products that use nanotechnology materials.
The task force will identify and recommend ways to address any knowledge or policy gaps that exist so as to better enable the agency to evaluate possible adverse health effects from FDA-regulated products that use nanotechnology materials. FDA will continue to address product-specific nanotechnology-related issues on an ongoing basis.
"As this exciting new area of science develops, FDA must be positioned to address both health promotion and protection challenges that it may present," said Dr. von Eschenbach. "Through this task force, we are leveraging our expertise and resources to guide the science and technology in the development of nanotechnology-based applications."
Specifically, the task force will:
- Chair a public meeting to help FDA further its understanding of developments in nanotechnology materials that pertain to FDA-regulated products, including new and emerging scientific issues such as those pertaining to biological interactions that may lead to either beneficial or adverse health effects. This public meeting is scheduled for October 10.
- Assess the current state of scientific knowledge pertaining to nanotechnology materials for purposes of carrying out FDA's mission.
- Evaluate the effectiveness of the agency's regulatory approaches and authorities to meet any unique challenge that may be presented by the use of nanotechnology materials in FDA-regulated products.
- Explore opportunities to foster innovation using nanotechnology materials to develop safe and effective drugs, biologics and devices, and to develop safe foods, feeds, and cosmetics.
- Continue to strengthen FDA's collaborative relationships with other federal agencies, including the agencies participating in the National Nanotechnology Initiative such as the National Institutes of Health (NIH), the Environmental Protection Agency (EPA), and the United States Department of Agriculture (USDA), as well as with foreign government regulatory bodies, international organizations, healthcare professionals, industry, consumers, and other stakeholders to gather information regarding nanotechnology materials used or that could be used in FDA-regulated products.
- Consider appropriate vehicles for communicating with the public about the use of nanotechnology materials in FDA-regulated products.
- Submit its initial findings and recommendations to the Acting Commissioner within nine months of the public meeting.
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
